Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Operating expense | 3.7M | 3% |
| Net Income | -18M | 219% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 4.8M | 36.3% |
| Total Liabilities | 40M | 23.5% |
| Shares Outstanding | 20M | 18.9% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -4M | 15.7% |
| Cash from financing | 1.4M | 81.7% |
EPS
Financial Highlights for NRx Pharmaceuticals in Q2 '25
Operating Expenses for this period were 3.7M, showing a -3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -18M, showing a -219% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
NRx Pharmaceuticals faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income.
